Regorafenib: New Option for Advanced Gastroesophageal Cancer?
SAN FRANCISCO — Patients with refractory advanced gastroesophageal cancer (AGOC) have a poor prognosis, with limited options following failure of second-line therapy. New data showing improved survival suggest that regorafenib (Stivarga) may offer a new treatment option in these patients.
"Regorafenib significantly improves survival compared with placebo in patients with refractory AGOC, delaying deterioration in global quality of life," said lead author Nick Pavlakis, PhD, MBBS, Royal North Shore Hospital, St. Leonards, Australia. "There were also no new toxicity signals."
He emphasized that benefit was consistent in all preplanned subgroups. "This offers a new treatment option in this setting," Pavlakis said.
Vous désirez lire la suite de cet article ?
Inscrivez-vous